Neuroimmune dysregulation is implicated in neuropsychiatric disorders including schizophrenia (SZ).
INTRODUCTION
22q11.2 deletion syndrome (22qDS, also known as DiGeorge's syndrome, velo-cardio-facial syndrome) is a genetic condition due to a 3 megabase hemizygous deletion of approximately 40 genes on chromosome 22 (Gur et al., 2017; Meechan et al., 2015) . These patients present with cardiac malformations, facial deformities, gastrointestinal disturbances, and intellectual disability, as well as increased rates of neuropsychiatric conditions including attention deficits, autism spectrum disorder, and schizophrenia (SZ) (Gur et al., 2017) . Remarkably, during adolescence and young adulthood roughly 25% of 22qDS patients develop SZ, a 25-fold increase in risk over the general population (Arinami, 2006; Karayiorgou & Gogos, 2004 ; Van, Boot, & Bassett, 2017) . The 22q11.2 deletion includes junctional and mitochondrial genes that could influence barrier function (Arinami, 2006; Devaraju & Zakharenko, 2017; Greene et al., 2018; Greene, Hanley, & Campbell, 2019) . However, the status of the blood brain barrier (BBB), the highly specialized central nervous system (CNS) endothelial cells, in 22qDS is unknown.
The vasculature of the BBB is composed of highly specialized endothelial cells characterized by specialized transport systems, higher mitochondrial volume fraction, and a paracellular cleft between adjacent endothelial membranes (Abbott, Rönnbäck, & Hansson, 2006; Obermeier, Daneman, & Ransohoff, 2013) . The anatomical basis of barrier function is due to an elaborated network of junctional proteins composed of tight junctions (TJs) and adherens junctions (AJs) (Alvarez et al., 2015; Muldoon et al., 2013; Zihni et al., 2016) . This network confers immune privilege to the CNS, by restricting interactions with the periphery (Abbott et al., 2010; Daneman & Prat, 2014; Engelhardt & Coisne, 2011; Muldoon et al., 2013) . Additionally, immunoquiescent properties of the BBB endothelium also contribute to CNS immune privilege, specifically by downregulating expression of cell adhesion molecules, cytokines and chemokines to impede leukocyte transmigration into the CNS (Alvarez et al., 2015; Daneman & Prat, 2014) . Interestingly, fluctuations of psychotic symptoms in SZ resemble the relapsing remitting pattern of prototypical immunological disorders, suggesting that the peripheral inflammation 5 22qDS+SZ iBBB exhibited substantially impaired barrier integrity, despite the genetic variability introduced by our approach. This phenotype was substantiated in vivo in a 22qDS mouse model harboring a homologous hemizygous deletion (Didriksen et al., 2017; Nilsson et al., 2018; Scarborough et al., 2019) . We further interrogated junctional protein expression and immune privilege properties of the BBB in vitro and in vivo. We assessed the functional consequences of compromised BBB by determining the propensity of the 22qDS BBB to permit immune cell migration and activation in vitro, and promote perivascular astrocyte activation in vivo. Our results indicate that the 22q11.2 deletion reduces BBB integrity, alters the immune privilege of the CNS vasculature, and increases the transendothelial migration of peripheral immune cells, suggesting that BBB dysfunction may contribute to the increased susceptibility to SZ in 22qDS patients.
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MATERIALS AND METHODS
Human induced pluripotent stem cells (HiPSCs)
HiPSC lines were generously received from Herbert M. Lachman, MD., Einstein University, Bronx, New York (15bc4, 553c2, 1804c6, 1bc4, 60c2, 30c1, and 3113c4 ) and Sergiu P. Pașca, MD., Stanford University, Stanford, California (1804 .5, 2788 . All lines were transferred over to a feeder-free system with Stem MACS iPS-Brew XF media . Lines were tested for mycoplasma using Lookout mycoplasma PCR detection kit (Sigma MP0035).
Differentiation of iPSCs into blood-brain barrier endothelium
HiPSCs were differentiated into BBB-like endothelium following the protocol previously published (Hollmann et al., 2017; Lippmann et al., 2012) . In brief, HiPSCs were plated onto Matrigel (Corning 354230) coated 6 well TC-treated plated (Falcon 353046) at 100,000 cells/well in Stem MACs iPS-Brew XF media. The following day (Day 0) media was fully exchanged (2 mLs) to unconditioned medium (UM): DMEM/Ham's F12 containing 20% Knockout Serum Replacer (Invitrogen), 1× MEM nonessential amino acids (Invitrogen), 1 mM l-glutamine (Sigma), 0.1 mM β-mercaptoethanol (Sigma).
Full exchanges were performed every day through Day 5. On day 6, media was fully exchanged (4 mLs) to endothelial cell medium (ECM): human Endothelial Serum-Free Medium (Invitrogen 11111) with 1% platelet-poor plasma-derived bovine serum (Biomedical Technologies 50-443-029) with 20 ng/mL bFGF (Peprotech 100-18B), and 10µM retinoic acid (RA; Sigma R2625). An addition 2 mLs of ECM with RA and bFGF was added on day 7. On Day 8, iBBB endothelial cells were frozen down.
Previous publications have extensively validated the iBBB cells produced by this differentiation protocol (Hollmann et al., 2017; Lippmann et al., 2012) ; to determine that the 22q11.2 deletion did not affect the differentiation process, we confirmed similar expression levels in vasculature-specific molecules by flow cytometry (Supplementary Figure 2) , and in junctional proteins by immunofluorescence (Supplementary Figure 1A) and western blot (Figure 2A ). 
iBBB TEER
The electrical properties of confluent monolayers of iBBB endothelial cells were measured as previously described (Alvarez, Dodelet-Devillers, et al., 2011) . In brief, the Electric Cell-substrate Impedance Sensing (ECIS) methodology was employed making using of the ECIS Zϴ instrument and 8W10E+ electrode arrays (Applied Biophysics, Troy, NY, USA). The TEER properties of iBBB cell monolayers were recorded at 2000 Hz over a period of 72 hrs. Resistance of the iBBB cell monolayers were assessed at confluency (determined as maximum resistance of the monolayer), and data is presented as fold change of the 22qDS+SZ iBBB, normalized to HC pair. 
Experiment
Cell
Density
Media
Volume
iBBB flow cytometry
Following 5 days in vitro, iBBB cells were detached with StemPro accutase (ThermoFisher Scientific A11105-01) and nonspecific binding was blocked with Mouse IgG Isotype Control (Invitrogen) for 25 minutes at 4 o C. Cells were stained with monoclonal mouse anti-human antibodies as shown in Table 2 for 30 minutes at 4 o C. Data was collected on LSRFortessa (BD Biosciences). Mean fluorescent intensity (MFI) of the ICAM-1 + population was measured with FlowJo version 10 software (BD biosciences).
ICAM-1 expression in each donor pair was analyzed in 2-4 separate experiments. 
Immune cell transmigration across iBBB monolayers
To investigate monocyte migration across the 22qDS BBB, we utilized a transwell model in which iBBB cells were grown on the upper chamber of 6.4 mm filter Falcon cell culture inserts (ThermoFisher Scientific) for 5 days. Monocytes were isolated from the blood of 8 healthy volunteers as previously described (Kebir et al., 2009 ). In brief, peripheral blood mononuclear cells were isolated using density gradient centrifugation on Ficoll-Paque TM (GE Healthcare). CD14 + cells were obtained using the MACS isolation columns according to the manufacturer's protocol (Miltenyi). CD14 + cells (1x10 6 per well) were allowed to migrate for 18 hours, and the activation state of migrated monocytes was assessed using flow cytometry immunostaining. Nonspecific binding was blocked with Mouse IgG Isotype Control (Invitrogen) for 25 minutes at 4 o C. Cells were stained with mouse anti-human antibodies shown in 
Mice
All experiments were conducted in accordance with IACUC at the University of Pennsylvania. 4-6month-old male and female 22qDS mice and WT littermates (Taconic) were anesthetized by either isofluorane or CO2 and transcardially perfused with ice cold PBS (1X). Brains were either frozen in Optimal Cutting Temperature (OCT) Compound (Fisher HealthCare) for sectioning, kept fresh in RPMI (1X)+GlutaMAX (Gibco) for flow cytometry or frozen at -80 o C for western blotting.
Mouse anterior cortex was thawed and sonicated in RIPA Lysis buffer (Amresco) on ice using an Ultrasonic Homogenizer (Biologics Inc.). Western blot analyses proceeded as described above. N=11
WT, 10 22qDS (15 males, 6 females).
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Mouse CNS endothelial cell flow cytometry
Microvascular endothelial cells were isolated from the anterior portion of the CNS for flow cytometry analysis as previously described (Crouch & Doetsch, 2018 analyses were performed blinded and using ImageJ, as previously described (Alvarez et al., 2015) .
Extravascular fibrinogen and IgG in the anterior cortex was quantified as the average pixel intensity of the leakage area; 12 vessels were analyzed from four 20x z stack maximum projections per animal.
Transected vessels stained for claudin-5 and ZO-1 in the anterior cortex were imaged in four 40x zstack maximum projections per animal. Average pixel intensity was measured at 3 points along each TJ strand and were averaged to a single measurement per TJ; 5 TJ strands from 5 different vessels were analyzed per animal. Vascular ICAM-1 expression was imaged in the anterior cortex in three 40x z-stack maximum projections per animal. Average pixel intensity was obtained at 3 points along each of the four brightest ICAM-1 positive vessels in each animal, and these were averaged to find the average pixel intensity of ICAM-1 per blood vessel. GFAP and IL-6 expression were imaged at 20x in the hippocampus; IL-6 expression was quantified as the average pixel intensity per astrocyte process, with a total of 10 processes analyzed per animal. N=10 (14 females, 6 males from 3 experiments) except assessment of barrier function (fibrinogen/IgG, Figure 1 ), in which 2 mice noted with poor CNS perfusion at time of brain harvest were excluded.
Human post-mortem samples
Using a clinical database of patients with 22qDS, three subjects with full post-mortem neuropathological examinations were identified for inclusion in this study (ages: 1, 2 and 14 months; all patients were female). A pathology database was queried to identify post-mortem samples from age-matched controls. Three controls with congenital heart disease (ages: 1, 1 and 16 months; M/F: 2/1) and two without congenital heart disease (ages: 1 and 12 months; all female) were included. All materials were obtained from pre-existing formalin-fixed, paraffin-embedded tissue of the frontal lobe and were histologically confirmed to contain both cortex and white matter. All materials from human subjects were de-identified in accordance with the Children's Hospital of Philadelphia Institutional Review Board requirements.
Immunohistofluorescence of paraffin embedded sections
Paraffin-embedded brains were immunostained as previously published (Alvarez et al., 2002) . In brief, sections from post mortem controls (n=3) and 22qDS patients (n=3) were sectioned and mounted on positively charged slides (ThermoFisher Scientific). Sections were deparaffinized by washing in xylene followed by washing in 100%, 95% and 70% ethanol followed by H2O. Epitope retrieval was performed in a microwave using citrate buffer pH 6.0 (Dako) for 30 minutes. performed in an Olympus IX83 as indicated above. IL-6 expression was quantified as average pixel intensity per astrocyte, 15 astrocytes analyzed per patient, using Adobe Photoshop.
Statistical analysis
Wilcoxon matched-pairs signed rank test was used for comparisons between HC and 22qDS+SZ iBBB experiments. ECIS -TEER statistical analysis was calculated by determining the effect of each genotype on the monolayer of endothelial cells using repeated measures one-way ANOVA. Unpaired student's t test was used for comparisons between WT and 22qDS mice. All data analysis was performed in GraphPad Prism 7 (GraphPad, San Diego, CA, USA). Values are presented as mean ± SEM. Graphical representations of p values are * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.
RESULTS
Barrier function is impaired in the 22qDS BBB
As the barrier function of CNS vascular endothelial cells underlies the ability of the BBB to restrict peripheral influences on CNS function (Abbott et al., 2010; Daneman & Prat, 2014) , we first assessed barrier properties of the 22qDS BBB. To evaluate the effect of the 22qDS deletion on barrier function, we obtained HiPSCs from 5 22qDS+SZ patients and 5 paired age-and sex-matched HCs. iBBB endothelial cells were derived from these HiPSCs using a differentiation protocol as previously described ( Figure 1A ) (Hollmann et al., 2017; Lippmann et al., 2012) . To interrogate the barrier function of the iBBB monolayers, we assessed their transendothelial electrical resistance (TEER) by repeatedly sampled resistance of the monolayers over the course of 72 hours. We observed a significant decrease in TEER of the 22qDS+SZ iBBB monolayers at confluency compared to paired HC monolayers ( Figure   1B ), indicating that barrier function of the BBB is compromised in 22qDS ( Figure 1C ).
To evaluate the 22qDS BBB in vivo, we utilized a mouse strain harboring a hemizygous deletion of the 22qDS homologous region on chromosome 16 (Didriksen et al., 2017; Nilsson et al., 2018; Scarborough et al., 2019) . These mice mimic much of the biology of 22qDS in humans, including facial deformities and SZ-associated behavioral changes (Didriksen et al., 2017; Nilsson et al., 2018; Scarborough et al., 2019) . We assessed BBB integrity by quantifying extravasation of blood proteins into the CNS parenchyma of 22qDS mice and their wild type (WT) littermates. Vasculature was cleared by transcardial perfusion, and immunofluorescent analyses demonstrated a significant increase in extravascular leakage of two serum proteins, immunoglobulin G (IgG) and fibrinogen ( Figure 1D -E) in 22qDS. Together, our results support the hypothesis that the BBB is intrinsically compromised in 22qDS. 
Claudin-5 expression is compromised in the 22qDS BBB
As our TEER results indicate impaired junctional integrity underlying compromised barrier function, we next analyzed tight junction protein expression in the 22qDS BBB. Because claudin-5 is the most densely expressed tight junction molecule in the BBB (Morita et al., 1999; Ohtsuki et al., 2007; Ohtsuki et al., 2008) and the gene for claudin-5 is included in the 22q11.2 deletion (Arinami, 2006; , we assessed claudin-5 expression in our iBBB endothelial cell cultures. There was no change in claudin-5 protein level between 22qDS+SZ and HC cultures by western blot (Figure 2 A-B ),
suggesting that compromised barrier integrity in 22qDS+SZ iBBB monolayers is not solely due to insufficient claudin-5 gene dosage. As the organization of tight junctions is critical for proper barrier function, we assessed claudin-5 localization in the paracellular cleft between endothelial cells, and observed highly disorganized expression in 22qDS+SZ iBBB cells (Figure 2 C-D) . This deficit was specific to claudin-5, as we did not observe any changes in the organization of the intracellular tight junction protein zona occludens 1 (ZO-1) (Supplementary Figure 1A) .
In contrast to in vitro claudin-5 expression, we observed reduced levels of claudin-5 in the brains of 
Immune privilege properties are affected in the 22qDS BBB
Given that the BBB serves as an immunological boundary between the periphery and the CNS (Abbott et al., 2010; Daneman & Prat, 2014; Engelhardt & Coisne, 2011; Muldoon et al., 2013) , and because of the renewed focus on the immune system in SZ (Miyaoka et al., 2017; Müller, 2018; Pollak et al., 2018; Severance et al., 2016; Wei & Hemmings, 2005) , we assessed the immunoquiescent properties of the 22qDS BBB. We evaluated expression of typical vascular markers (melanoma cell adhesion molecule, MCAM, CD146; thrombomodulin, TM, CD141) (Larochelle et al., 2012; Rochfort & Cummins, 2015; Tran et al., 1996) and those known to be upregulated during inflammation/stress (intercellular cell adhesion molecule 1, ICAM-1, CD54; vascular cell adhesion molecule 1, VCAM-1, CD106) (Alvarez et al., 2015; Daneman & Prat, 2014; Dietrich, 2002; Muldoon et al., 2013) . We found no change in vascular marker expression ( Supplementary Figure 2A-B) indicating that the iBBB differentiation process was unaffected by the 22q11.2 deletion. However, we found significantly elevated ICAM-1 expression in 22qDS+SZ iBBB endothelial cells compared to HC pairs ( Figure 3A-B ), suggesting immune activation of the 22qDS BBB endothelium. As expected, we did not observe any change in VCAM-1 expression ( Supplementary Figure C) , which is no detected on the BBB under homeostatic conditions (J.I Alvarez, personal communication 11/19).
To assess the immunological properties of the 22qDS BBB in vivo, we isolated vascular endothelial cells from the brain of WT and 22qDS mice and determined their cell adhesion molecule expression by flow cytometry. As in our iBBB cultures, we again observed a significant increase in ICAM-1 expression on CNS endothelial cells in 22qDS (Figure 3 C-D) . In situ analysis of 22qDS and WT PFC sections 
22qDS BBB promotes monocyte migration and activation
To assess the functional consequences of compromised barrier function and immune properties of the 22qDS BBB, we migrated human immune cells across iBBB endothelial cell monolayers ( Figure 4A ).
We found that iBBB monolayers derived from 22qDS+SZ patients were less able to restrict migration of human monocytes ( Figure 4B) . To determine the effect of transendothelial migration, we assessed expression of monocyte/macrophage markers of activation and migration on transmigrated monocytes ( Figure 4C, Supplementary Figure 3 ). We found that following migration across 22qDS+SZ iBBB monolayer, monocytes significantly decreased thrombomodulin (TM, CD141) expression ( Figure 4D -E). As TM is known to be an anti-inflammatory molecule expressed on both immune cells and the luminal endothelium to inhibit immune cell adherence and extravasation (Loghmani & Conway, 2018; van de Ven et al., 2013; Xu et al., 2015) , our findings indicate that the 22qDS+SZ BBB has a promigratory effect on immune cells. 
Perivascular astrocytes are activated in 22qDS
We next aimed to assess the functional consequences of compromised barrier function in 22qDS mice.
As astrocytic endfeet ensheath the CNS vasculature (Abbott et al., 2006; Cheslow & Alvarez, 2016) , and because we have found that 22qDS mice have elevated perivascular fibrinogen, a molecule that is highly pro-inflammatory in the CNS (Davalos et al., 2012; Schachtrup et al., 2010) , we evaluated astrocyte activation by glial fibrillary acidic protein (GFAP) expression. We observed upregulation of GFAP in the brains of 22qDS mice compared to WT, indicating widespread astrocyte activation.
Interestingly, this astrocyte activation appeared to be mainly along the CNS vasculature of the meninges ( Figure 5A ). In order to characterize the activation of astrocytes in 22qDS, we focused our analyses on the pro-inflammatory cytokine IL-6, as this molecule has been repeatedly shown to be elevated in the blood of both idiopathic SZ patients and 22qDS+SZ patients (Khandaker et al., 2014; Mekori-Domachevsky et al., 2017; Potvin et al., 2008; Subbanna et al., 2018a) . We found that IL-6 expression was significantly upregulated in astrocytes bordering large CNS vessels of the meninges in 22qDS mice ( Figure 5B ), suggesting that this activation may not be solely due to intrinsic astrocyte defects, but rather a consequence of compromised barrier function in the 22qDS CNS.
To determine the status of neurovascular astrocytes in human 22qDS patients, we obtained post mortem brain sections from 3 22qDS patients and 3 age-matched HCs. Immunofluorescent staining for GFAP and IL-6 indicated elevated astrocyte activation and IL-6 expression in 22qDS patients compared to HCs ( Figure 5C ). Together this data further validates that neuroimmune vascular activation in 22qDS involves the astroglial compartment. 
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DISCUSSION
For the first time, our results indicate BBB dysfunction in the context of 22qDS, the strongest monogenic risk allele for SZ (Gur et al., 2017) . These results are supported by clinical data suggesting that barrier function and immune privilege properties of the BBB are affected in idiopathic SZ patients. Multiple studies have reported that SZ is associated with elevated serum proteins such as immunoglobulins and albumin in the cerebrospinal fluid (CSF), consistent with compromised barrier function (Endres et al., 2015; Severance et al., 2015) . Similarly, we have found increased extravasation of serum proteins into the CNS parenchyma in 22qDS mice compared to WT, and this finding of compromised barrier function is further supported by impaired TEER in our 22qDS+SZ iBBB monolayers.
Polymorphisms in the claudin-5 gene have been associated with SZ Omidinia et al., 2014; Sun et al., 2004; Wu et al., 2009) , including recent work by our lab demonstrating an association between the claudin-5 rs10314 variant and SZ diagnosis in a large cohort female 22qDS
patients (Guo et al., 2019) . Furthermore, claudin-5 mRNA and protein expression is decreased in the post mortem SZ brain compared to controls (Nishiura et al., 2017) . To our surprise, our 22qDS+SZ and HC iBBBs expressed indistinguishable levels of claudin-5 protein, while 22qDS mice expressed significantly less claudin-5 than WT. Rather, altered claudin-5 organization within the paracellular cleft of endothelial cells appears to underlie the compromised barrier function in 22qDS+SZ iBBBs. This contrast between in vivo and in vitro data suggests that the effects of the 22q11.2 deletion on barrier function are not solely due to claudin-5 gene dosage, but more likely due to an interaction of genes in the deleted region or an exaggerated stress response in vitro. Of note are the 6 mitochondrial genes in the 22q11.2 deleted region (Maynard et al., 2008; Napoli et al., 2015) , which may further contribute to compromise the BBB given the impaired mitochondrial function reported in other CNS cell populations in 22qDS (Fernandez et al., 2019; Li, Ryan, et al., in press ). Furthermore, we have found that ICAM-1 is upregulated in the BBB, implicating differences in inflammatory/stress responses in 22qDS (Alvarez, Cayrol, et al., 2011; Daneman & Prat, 2014; Dietrich, 2002) . Alternatively, other factors in vivo, including circulating pro-inflammatory molecules and/or the close association with astrocyte endfeet (Abbott et al., 2006; Cheslow & Alvarez, 2016) , may alter the effects of the deletion on the BBB in vivo compared to in vitro.
In addition to compromised barrier function of the BBB, it has also been reported that immunoquiescent
properties of the CNS vasculature may be disrupted in SZ patients (Nguyen et al., 2018) . Postmortem studies have indicated elevated expression of the pro-inflammatory cell adhesion molecule ICAM-1 in the CNS endothelium of SZ patients (Cai et al., 2018) , which may contribute to the increased presence of peripheral immune cells within the CNS parenchyma in post mortem SZ brains (Khandaker et al., 2015) . We have also found an increase in ICAM-1 expression in both our 22qDS+SZ iBBB cells and in vascular endothelial cells isolated from the CNS of 22qDS mice. This may contribute to the increase in immune cell migration across the 22qDS+SZ iBBB monolayer. We postulate that the increase in ICAM-1 expression in 22qDS mice may represent an exacerbated immune sensitivity to facilitate leukocyte migration into the CNS upon environmental stress, such as infection or injury.
Using the 22qDS mice, we were able to probe beyond the BBB to interrogate the status of the neurovascular unit. As we had found compromised barrier function in vivo and because fibrinogen is known to be a highly pro-inflammatory molecule in the CNS (Davalos et al., 2012; Schachtrup et al., 2010) , we hypothesized that this may contribute to astrocyte activation. Our observations build upon previous findings of astrogliosis in the post mortem 22qDS brain (Kiehl et al., 2009 ) and we report our novel finding that astrocyte activation in 22qDS is associated with significantly increased astrocytic IL-6 expression. Notably, we observed that IL-6 expression was elevated primarily in astrocytes lining the meningeal CNS vasculature in 22qDS mice. Although we cannot attribute our observations of astrogliosis in 22qDS mice specifically to compromised BBB, the pattern of astrocyte activation predominantly along large CNS vessels suggests that impaired barrier function may contribute to astrocyte-mediated neuroinflammation in 22qDS (Muradashvili, Tyagi, & Lominadze, 2017; Schachtrup et al., 2010; Verkhratsky & Nedergaard, 2018) . Interestingly, we observed that IL-6 is primarily upregulated by perivascular astrocytes in the hippocampus, a region that has been implicated in clinical SZ patients and behavioral deficits in 22qDS mice (Kalmady et al., 2017; Lieberman et al., 2018; Sauras et al., 2017; S. Anderson, personal communication 11-2019) . These results suggest potential mechanisms by which compromised BBB may contribute to the neuronal dysfunction that has previously been reported in 22qDS mice, and future studies could address a causal relationship between BBB impairment and altered neuronal signaling.
Although our approach of utilizing HiPSC lines derived from 5 different 22qDS+SZ human donors introduces more variability into our data than typical in vitro studies, our consistent results despite our use of genetically different cell lines further reinforces our conclusions that barrier function and immune
properties of the BBB are disrupted in 22qDS+SZ. It is important to note that in both our human 22qDS+SZ iBBB cultures and our human 22qDS+SZ brain sections, we cannot determine the role of SZ diagnosis in our results. It is unclear whether all 22qDS patients present with compromised barrier function, impaired claudin-5 structure, and elevated ICAM-1 expression, which together may contribute to the increased risk for neuropsychiatric conditions in this population, or whether these results are only evident in 22qDS patients that develop SZ. As our murine data indicate BBB dysfunction in naïve 22qDS mice, we hypothesize that our results are conferred by the deletion alone, regardless of SZ diagnosis, and therefore may contribute to the increased susceptibility to SZ and other neuropsychiatric disorders in 22qDS (Fiksinski et al., 2018; Fiorentino et al., 2016; Gandal et al., 2018; Kealy et al., 2018; Schneider et al., 2014) , but future studies including a 22qDS without SZ group will be important to address these questions.
This is the first study to assess the status of the BBB in the context of 22qDS, a population known to have a 25% increased risk of developing SZ (Arinami, 2006; Karayiorgou & Gogos, 2004; Van et al., 2017) . Our results support the hypothesis that neuroinflammation and compromised BBB may play a role in the pathogenesis of neuropsychiatric disorders. Fundamental to this hypothesis is the clinical data indicating peripheral inflammation in a subpopulation of SZ patients, including elevated peripheral 30 cytokines (most notably IL-6) and immune cell activation (especially of Th17 cells) (Debnath & Berk, 2014; Potvin et al., 2008; Subbanna et al., 2018b) . Interestingly, 22qDS patients present with a similar inflammatory profile, as they also have elevated peripheral IL-6 and increased percentages of circulating Th17 cells (Mekori-Domachevsky et al., 2015; O'Rourke & Murphy, 2019; Vergaelen et al., 2018) . Furthermore, a key component to the association between this reported immune activation and SZ is that BBB disruption facilitates CNS inflammation and neuronal dysfunction. Our results suggest that 22qDS may represent a uniquely appropriate condition to assess the role of peripheral inflammation and BBB dysfunction in neuropsychiatric disorders like SZ. 
